{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:51:03Z","timestamp":1794275463348,"version":"4.9.0"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T00:00:00Z","timestamp":1693267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Pulmonary hypertension due to chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD) is classified as group 3 pulmonary hypertension. Inhaled treprostinil, a prostaglandin I<jats:sub>2<\/jats:sub> analogue also known as prostacyclin, has recently been approved as a first drug for patients with pulmonary hypertension secondary to ILD. However, due to a lack of evidence, no therapies are currently approved for those with COPD-associated pulmonary hypertension. Thus, this systematic review aims to summarise the current evidence to assess the impact of inhaled prostaglandin I<jats:sub>2<\/jats:sub> analogue use on the pulmonary hemodynamics, exercise function, lung function, and gas exchange in patients with pulmonary hypertension due to COPD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We systematically searched the electronic databases of Medline, Embase, Scopus and Cochrane from inception to 1 February 2023. Studies of adult patients with a confirmed diagnosis of COPD-associated pulmonary hypertension who received inhaled drugs targeting the prostacyclin pathway were included in the systematic review. Case reports, systematic reviews, conference abstracts with no full text, non-full-text articles, non-English manuscripts and book chapters were excluded from this systematic review. A risk-of-bias assessment was carried out for the studies included in this review, using two different Cochrane risk-of-bias tools for randomised and non-randomised clinical trials.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of four studies met our inclusion criteria and were included in this systematic review. The results of one prospective clinical trial showed an improvement in the pulmonary hemodynamics (e.g., cardiac index, cardiac output and mean pulmonary artery pressure) in response to inhaled prostacyclin use in patients with pulmonary hypertension secondary to COPD. However, the severity of dyspnoea, lung function, exercise capacity and gas exchange were not affected when inhaled prostacyclin was used for patients with COPD-related pulmonary hypertension.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This systematic review demonstrated that although inhaled prostacyclin does not seem to improve COPD-related outcomes (e.g., lung function and exercise capacity), short-term use of inhaled prostacyclin has the potential to reduce mean pulmonary artery pressure and pulmonary vascular resistance without impairing ventilation-perfusion mismatch. Further studies with larger sample sizes are warranted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p>CRD42022372803, <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?RecordID=372803<\/jats:ext-link>.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2023.1217156","type":"journal-article","created":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T02:21:15Z","timestamp":1693362075000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Inhaled therapies targeting prostacyclin pathway in pulmonary hypertension due to COPD: systematic review"],"prefix":"10.3389","volume":"10","author":[{"given":"Abdullah A.","family":"Alqarni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulelah M.","family":"Aldhahir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heba M.","family":"Bintalib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaber S.","family":"Alqahtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayan A.","family":"Siraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansour","family":"Majrshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulkareem A.","family":"AlGarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdallah Y.","family":"Naser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara A.","family":"Alghamdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Alwafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,8,29]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1801913","DOI":"10.1183\/13993003.01913-2018","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary hypertension","volume":"53","author":"Simonneau","year":"2019","journal-title":"Eur Respir J"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1056\/NEJM197204272861703","article-title":"Patterns of cardiovascular dysfunction in chronic obstructive lung disease","volume":"286","author":"Burrows","year":"1972","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1136\/thx.36.10.752","article-title":"Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease","volume":"36","author":"Weitzenblum","year":"1981","journal-title":"Thorax"},{"key":"ref5","first-page":"993","article-title":"Long-term course of pulmonary arterial pressure in chronic obstructive pulmonary disease","volume":"130","author":"Weitzenblum","year":"1984","journal-title":"Am Rev Respir Dis"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1159\/000195950","article-title":"Pulmonary hemodynamics in chronic obstructive pulmonary disease of the emphysematous type","volume":"58","author":"Oswald-Mammosser","year":"1991","journal-title":"Respiration"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1164\/rccm.2107027","article-title":"Hemodynamic characterization of patients with severe emphysema","volume":"166","author":"Scharf","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1164\/rccm.200210-1130OC","article-title":"Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease","volume":"167","author":"Arcasoy","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1164\/rccm.200401-006OC","article-title":"Severe pulmonary hypertension and chronic obstructive pulmonary disease","volume":"172","author":"Chaouat","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1378\/chest.127.5.1531","article-title":"Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation","volume":"127","author":"Thabut","year":"2005","journal-title":"Chest"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"356","DOI":"10.18203\/2349-3933.ijam20181061","article-title":"Prevalence of pulmonary hypertension in COPD","volume":"5","author":"Katiyar","year":"2018","journal-title":"Int J Adv Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.2147\/COPD.S211841","article-title":"Updated perspectives on pulmonary hypertension in COPD","volume":"15","author":"Blanco","year":"2020","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1159\/000524263","article-title":"The effect of borderline pulmonary hypertension on survival in chronic lung disease","volume":"101","author":"Piccari","year":"2022","journal-title":"Respiration"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12931-022-02056-z","article-title":"Imbalanced prostanoid release mediates cigarette smoke-induced human pulmonary artery cell proliferation","volume":"23","author":"Alqarni","year":"2022","journal-title":"Respir Res"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3390\/medicina59010165","article-title":"Increased thromboxane a(2) levels in pulmonary artery smooth muscle cells isolated from patients with chronic obstructive pulmonary disease","volume":"59","author":"Alqarni","year":"2023","journal-title":"Medicina"},{"key":"ref16","first-page":"11","article-title":"A review of pulmonary arterial hypertension: role of ambrisentan","volume":"3","author":"Barst","year":"2007","journal-title":"Vasc Health Risk Manag"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1183\/09031936.00097107","article-title":"Prostacyclin therapies for the treatment of pulmonary arterial hypertension","volume":"31","author":"Gomberg-Maitland","year":"2008","journal-title":"Eur Respir J"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ahj.2013.08.007","article-title":"EPITOME-2: an open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension","volume":"167","author":"Sitbon","year":"2014","journal-title":"Am Heart J"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","article-title":"Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial","volume":"165","author":"Simonneau","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1183\/09031936.00137511","article-title":"Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension","volume":"40","author":"Simonneau","year":"2012","journal-title":"Eur Respir J"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa020204","article-title":"Inhaled iloprost for severe pulmonary hypertension","volume":"347","author":"Olschewski","year":"2002","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/S0735-1097(02)01786-2","article-title":"Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial","volume":"39","author":"Gali\u00e8","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.healun.2009.09.005","article-title":"Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial","volume":"29","author":"Hiremath","year":"2010","journal-title":"J Heart Lung Transplant"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.chest.2021.02.012","article-title":"Pulmonary hypertension in patients with COPD: results from the comparative, prospective registry of newly initiated therapies for pulmonary hypertension (COMPERA)","volume":"160","author":"Vizza","year":"2021","journal-title":"Chest"},{"key":"ref25","first-page":"1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume-title":"Syst Rev","author":"Moher","year":"2015"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1086\/689291","article-title":"The safety and tolerability of inhaled treprostinil in patients with pulmonary hypertension and chronic obstructive pulmonary disease","volume":"7","author":"Bajwa","year":"2017","journal-title":"Pulmonary Circulation"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"e52248","DOI":"10.1371\/journal.pone.0052248","article-title":"Acute effects of aerosolized iloprost in COPD related pulmonary hypertension - a randomized controlled crossover trial","volume":"7","author":"Boeck","year":"2012","journal-title":"PLoS One"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.2147\/COPD.S141798","article-title":"Hemodynamic and gas exchange effects of inhaled iloprost in patients with COPD and pulmonary hypertension","volume":"12","author":"Wang","year":"2017","journal-title":"Int J COPD"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1159\/000242498","article-title":"Iloprost improves gas exchange and exercise tolerance in patients with pulmonary hypertension and chronic obstructive pulmonary disease","volume":"79","author":"Dernaika","year":"2010","journal-title":"Respiration"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.jacc.2010.01.027","article-title":"Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial","volume":"55","author":"McLaughlin","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1056\/NEJMoa2008470","article-title":"Inhaled Treprostinil in pulmonary hypertension due to interstitial lung disease","volume":"384","author":"Waxman","year":"2021","journal-title":"N Engl J Med"},{"key":"ref35","year":"2018"},{"key":"ref36","year":"2023"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"2200879","DOI":"10.1183\/13993003.00879-2022","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"61","author":"Humbert","year":"2022","journal-title":"Eur Respir J"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/S2213-2600(21)00165-X","article-title":"Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study","volume":"9","author":"Nathan","year":"2021","journal-title":"Lancet Respir Med"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"e001310","DOI":"10.1136\/bmjresp-2022-001310","article-title":"Study design and rationale for the TETON phase 3, randomised, controlled clinical trials of inhaled treprostinil in the treatment of idiopathic pulmonary fibrosis","volume":"9","author":"Nathan","year":"2022","journal-title":"BMJ Open Respir Res"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1183\/09031936.00033007","article-title":"Estimating pulmonary artery pressures by echocardiography in patients with emphysema","volume":"30","author":"Fisher","year":"2007","journal-title":"Eur Respir J"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1378\/chest.08-0820","article-title":"Pulmonary vascular involvement in COPD","volume":"134","author":"Peinado","year":"2008","journal-title":"Chest"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1164\/rccm.200907-0988OC","article-title":"Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension","volume":"181","author":"Blanco","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1136\/thorax.58.4.289","article-title":"Controlled prospective randomised trial on the effects on pulmonary haemodynamics of the ambulatory long term use of nitric oxide and oxygen in patients with severe COPD","volume":"58","author":"Vonbank","year":"2003","journal-title":"Thorax"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1183\/09031936.00011308","article-title":"A randomised, controlled trial of bosentan in severe COPD","volume":"32","author":"Stolz","year":"2008","journal-title":"Eur Respir J"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"D109","DOI":"10.1016\/j.jacc.2013.10.036","article-title":"Pulmonary hypertension in chronic lung diseases","volume":"62","author":"Seeger","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1161\/hc3601.096826","article-title":"Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension","volume":"104","author":"Wilkens","year":"2001","journal-title":"Circulation"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1217156\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T02:21:20Z","timestamp":1693362080000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1217156\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,29]]},"references-count":46,"alternative-id":["10.3389\/fmed.2023.1217156"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1217156","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fmed.2023.1217156.s001","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fmed.2023.1217156.s002","asserted-by":"subject"}]},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,29]]},"article-number":"1217156"}}